<SEC-DOCUMENT>0000950142-24-002011.txt : 20240726
<SEC-HEADER>0000950142-24-002011.hdr.sgml : 20240726
<ACCEPTANCE-DATETIME>20240725195850
ACCESSION NUMBER:		0000950142-24-002011
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20240725
FILED AS OF DATE:		20240726
DATE AS OF CHANGE:		20240725

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AURORA CANNABIS INC
		CENTRAL INDEX KEY:			0001683541
		STANDARD INDUSTRIAL CLASSIFICATION:	MEDICINAL CHEMICALS & BOTANICAL PRODUCTS [2833]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			A1
		FISCAL YEAR END:			0331

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38691
		FILM NUMBER:		241143322

	BUSINESS ADDRESS:	
		STREET 1:		2207 90B STREET SW
		CITY:			EDMONTON
		STATE:			A0
		ZIP:			T6X 1V8
		BUSINESS PHONE:		604-362-5207

	MAIL ADDRESS:	
		STREET 1:		409 GRANVILLE STREET
		STREET 2:		SUITE 1700
		CITY:			VANCOUVER
		STATE:			A1
		ZIP:			V6C 1T2
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>eh240512751_6k.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 12pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center"><B>FORM 6-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center"><B>REPORT OF FOREIGN PRIVATE ISSUER PURSUANT
TO RULE 13a-16 OR 15d-16</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>UNDER THE SECURITIES EXCHANGE ACT OF 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center">For the month of&nbsp;<B>July 2024</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center">Commission File No.&nbsp;<B>001-38691</B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center"><B><U>AURORA CANNABIS INC.</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(Translation of registrant's name into English)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>2207 90B St. SW</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Edmonton, Alberta T6X 1V8</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Canada</B><BR>
(Address of principal executive office)</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 12pt; margin-bottom: 0">Indicate by check mark whether the registrant files or will file
annual reports under cover of Form 20-F or Form 40-F</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center">Form 20-F&nbsp;&nbsp;<FONT STYLE="font-family: Segoe UI Symbol,sans-serif">&#9744;</FONT>&nbsp;Form
40-F&nbsp;&nbsp;<FONT STYLE="font-family: Segoe UI Symbol,sans-serif">&#9746;</FONT></P>

<P STYLE="font: 1pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 12pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>EXPLANATORY NOTE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">This current report on Form 6-K is being furnished with an updated version
of Exhibit 99.1, the news release dated July 25, 2024, which corrects certain textual errors contained therein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><B>SUBMITTED HEREWITH</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 8pt; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="width: 8%; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 10pt"><B>Exhibits</B></FONT></TD>
    <TD STYLE="vertical-align: top; width: 2%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 90%; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt"><B>Description&nbsp;</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 10pt">99.1</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt"><A HREF="eh240512751_ex9901.htm">News Release dated July 25, 2024</A></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center"><B>&nbsp;</B></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center"><B>SIGNATURE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0">Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 40%; font-size: 8pt; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><FONT STYLE="font-size: 10pt"><B>AURORA CANNABIS INC.</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">/s/ <I>Miguel Martin</I></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Miguel Martin</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Chief Executive Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0">Date: July 25, 2024</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>eh240512751_ex9901.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0"><B>EXHIBIT 99.1</B></P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;<IMG SRC="logo.jpg" ALT=""></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 8pt; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; font: 10pt Calibri, Helvetica, Sans-Serif; text-underline-color: black"><FONT STYLE="font-family: Times New Roman, Times, Serif">July 25, 2024</FONT></TD>
    <TD STYLE="width: 50%; font: 10pt Calibri, Helvetica, Sans-Serif; text-align: right; text-underline-color: black"><FONT STYLE="font-family: Times New Roman, Times, Serif">NASDAQ | TSX: ACB</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 12pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 4pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: windowtext"></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 6pt 0pt 0pt; text-align: center"><FONT STYLE="background-color: white"><B>Aurora Receives
Expanded Cultivation and Unique Research Licenses for German Facility </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: center"><FONT STYLE="background-color: white"><I>Company&rsquo;s
Long-Standing Investment in the Region Continues with Enhanced Local Production and Domestic Cultivar Research </I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"><B>Edmonton, AB &ndash; July
25, 2024</B> &ndash; Aurora Cannabis Inc. (the &quot;<B>Company</B>&quot; or &quot;<B>Aurora</B>&quot;) (NASDAQ | TSX: ACB), <FONT STYLE="background-color: white">a
leading Canadian-based global medical cannabis company, has been granted two licenses by the Federal Institute for Drugs and Medical Devices
(BfArM) under Germany's new Medical Cannabis Act (MedCanG). Aurora&rsquo;s license grants the company continued domestic cultivation,
which has been underway for two years now. Under the new license, Aurora may also cultivate an approved additional product, and plans
to expand their offerings to the rapidly growing German patient base. Aurora will also receive a dedicated R&amp;D license, allowing for
the trial of up to seven additional novel cultivars at the company&rsquo;s local EU GMP facility in Leuna, Germany. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"><FONT STYLE="background-color: white">&ldquo;We
thank the German government for its continued investment in the growth of medical cannabis, made possible by decriminalization, which
will improve access to medical cannabis for patients all across Germany,&rdquo; says Michael Simon, President, Aurora Europe. &ldquo;Being
one of the few companies to receive enhanced licenses is a testament to Aurora&rsquo;s established leadership in the region and unparalleled
commitment to making available the highest quality cannabis. We now have the framework to extend our portfolio, invest in domestic research
and leverage Aurora&rsquo;s global cultivation expertise locally.&rdquo;&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Aurora
is committed to the growth, acceptance and broader access to medical cannabis globally. The company's leadership in Europe is a result
of ongoing collaboration with government, regulators and industry. </FONT><FONT STYLE="background-color: white">Since 2021, Aurora&rsquo;s
medical cannabis production facility, located in Leuna, Saxony-Anhalt, has been cultivating approximately 1,000 kg (about 2204 lb) of
medical cannabis flower annually as part of a tender agreement with BfArM. The company has demonstrated a commitment to superior quality
and product efficacy that has led to the granting of additional licenses.&nbsp;These additional licenses are a result of the company&rsquo;s
continued focus on quality and compliance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"><FONT STYLE="background-color: white">The
company supports Germany&rsquo;s investment in meaningful regulatory reform, and anticipates it will have broader effect on the expanding
acceptance of medical cannabis and future modern frameworks across Europe. Aurora&rsquo;s domestic and global expertise in developing
novel, high quality and innovative products, positions the company as a differentiated leader, poised to fulfill growing patient demand.
</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>About Aurora Cannabis</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Aurora is opening the world to cannabis, serving both
the medical and consumer markets across&nbsp;Canada,&nbsp;Europe,&nbsp;Australia,&nbsp;and&nbsp;South America. Headquartered in&nbsp;Edmonton,
Alberta, Aurora is a pioneer in global cannabis, dedicated to helping people improve their lives. The Company's adult- use brand portfolio
includes Aurora Drift, San Rafael '71, Daily Special, Tasty's, Being and Greybeard. Medical cannabis brands include MedReleaf, CanniMed,
Aurora and Whistler Medical Marijuana Co, as well as international brands, Pedanios, Bidiol, IndiMed and CraftPlant. Aurora also has a
controlling interest in Bevo Farms Ltd.,&nbsp;North America's&nbsp;leading supplier of propagated agricultural plants. Driven by science
and innovation, and with a focus on high-quality cannabis products, Aurora's brands continue to break through as industry leaders in the
medical, wellness and adult recreational markets wherever they are launched. Learn more at&nbsp;www.auroramj.com&nbsp;and follow us on
X and LinkedIn.&nbsp;</P>

<P STYLE="font: 10pt Segoe UI, Helvetica, Sans-Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Aurora's common shares trade on the NASDAQ and TSX
under the symbol &quot;ACB&quot;.&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt"><B>Contact</B></P>



<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 8pt Calibri, Helvetica, Sans-Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 30%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For Media:</FONT></TD>
    <TD STYLE="width: 70%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For Investors:</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Michelle Lefler</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ICR, Inc.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">VP, Communications &amp; PR</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>aurora@icrinc.com</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 8pt 0pt; text-align: justify"><B>media@auroramj.com</B></P>



<DIV STYLE="border-bottom: Black 2pt dashed; padding: 0in 0in 26pt"></div>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 24pt 0pt 8pt; text-align: justify"><B>Forward Looking Information</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">This news release includes statements containing
certain &quot;forward-looking information&quot; within the meaning of applicable securities law (&quot;forward-looking statements&quot;).
Forward-looking statements are frequently characterized by words such as &quot;plan&quot;, &quot;continue&quot;, &quot;expect&quot;, &quot;project&quot;,
&quot;intend&quot;, &quot;believe&quot;, &quot;anticipate&quot;, &quot;estimate&quot;, &quot;may&quot;, &quot;will&quot;, &quot;potential&quot;,
&quot;proposed&quot; and other similar words, or statements that certain events or conditions &quot;may&quot; or &quot;will&quot; occur.
Forward-looking statements made in this news release include statements regarding the receipt of cultivation and R&amp;D licenses for
the Company&rsquo;s German facility and associated benefits including continued domestic cultivation, approved additional products and
the ability to further expand offerings in the German medical market; statements regarding the Company&rsquo;s competitive advantages
in domestic and global expertise, future plans, and the impact of the de-scheduling of cannabis on the expansion and acceptance of medical
cannabis and future modern frameworks across Europe.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">These forward-looking statements are only
predictions. Forward looking information or statements contained in this news release have been developed based on assumptions
management considers to be reasonable. Material factors or assumptions involved in developing forward-looking statements include,
without limitation, publicly available information from governmental sources </P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">as well as from market research and industry analysis
and on assumptions based on data and knowledge of this industry which the Company believes to be reasonable. Forward-looking
statements are subject to a variety of risks, uncertainties and other factors that management believes to be relevant and reasonable
in the circumstances could cause actual events, results, level of activity, performance, prospects, opportunities or achievements to
differ materially from those projected in the forward-looking statements. These risks include, but are not limited to, the ability
to retain key personnel, the ability to continue investing in infrastructure to support growth, the ability to obtain financing on
acceptable terms, the continued quality of our products, customer experience and retention, the development of third party
government and nongovernment consumer sales channels, management's estimates of consumer demand in Canada and in jurisdictions where
the Company exports, expectations of future results and expenses, the risk of successful integration of acquired business and
operations, management's estimation that SG&amp;A will grow only in proportion of revenue growth, the ability to expand and maintain
distribution capabilities, the impact of competition, the general impact of financial market conditions, the yield from cannabis
growing operations, product demand, changes in prices of required commodities, competition, and the possibility for changes in laws,
rules, and regulations in the industry, epidemics, pandemics or other public health crises, and other risks, uncertainties and
factors set out under the heading &quot;Risk Factors&quot; in the Company's annual information form dated June 20, 2024 (the
&quot;AIF&quot;) and filed with Canadian securities regulators available on the Company's issuer profile on SEDAR at
www.sedarplus.com and filed with and available on the SEC's website at www.sec.gov. The Company cautions that the list of risks,
uncertainties and other factors described in the AIF is not exhaustive and other factors could also adversely affect its results.
Readers are urged to consider the risks, uncertainties and assumptions carefully in evaluating the forward-looking statements and
are cautioned not to place undue reliance on such information. The Company is under no obligation, and expressly disclaims any
intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events
or otherwise, except as expressly required by applicable securities law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">&nbsp;</P>





<P STYLE="margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>logo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 logo.jpg
M_]C_X  02D9)1@ ! @$ 8 !@  #__@ 23$5!1%1/3TQ3('8R,BXP /_; (0
M!04%" 4(# <'# P)"0D,#0P,# P-#0T-#0T-#0T-#0T-#0T-#0T-#0T-#0T-
M#0T-#0T-#0T-#0T-#0T-#0T-#0$%" @*!PH,!P<,#0P*# T-#0T-#0T-#0T-
M#0T-#0T-#0T-#0T-#0T-#0T-#0T-#0T-#0T-#0T-#0T-#0T-#0T-_\0!H@
M 04! 0$! 0$           $" P0%!@<("0H+ 0 # 0$! 0$! 0$!
M 0(#! 4&!P@)"@L0  (! P,"! ,%!00$   !?0$" P $$042(3%!!A-180<B
M<10R@9&A""-"L<$54M'P)#-B<H()"A87&!D:)28G*"DJ-#4V-S@Y.D-$149'
M2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@X2%AH>(B8J2DY25EI>8F9JB
MHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2T]35UM?8V=KAXN/DY>;GZ.GJ
M\?+S]/7V]_CY^A$  @$"! 0#! <%! 0  0)W  $" Q$$!2$Q!A)!40=A<1,B
M,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF)R@I*C4V-S@Y.D-$149'
M2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$A8:'B(F*DI.4E9:7F)F:
MHJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7V-G:XN/DY>;GZ.GJ
M\O/T]?;W^/GZ_\  $0@ -0#= P$1  (1 0,1 ?_:  P# 0 "$0,1 #\ ^RZ
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M0;F6">*4JN<9(C9B!GC)XSQ0!J331VT;33,L<<:EW=B%55499F8X"JH!))(
M R>* ,2R\5Z-J4RVUG?V5Q.^=L4-S#)(V 6.U$<L<*"QP. "3P* -'4=4L](
MC$]_/#:1%@HDGD2)-Q!(7<[*NX@$@9R0#Z4 0:9KNG:R7&G75M>&+&_[/-'-
MLW9V[O+9MN[:V,XS@XZ&@"M>^*M&TR8VU[?V=M,F-T<US#&Z[@&&4=PPR"",
MCD$$<4 5?^$X\/?]!33O_ RW_P#CE &]9WUOJ$8FM)8YXST>)U=?^^E)'ZT
M6NE '':E\0O#FCR&&\U&TBE4X9/.1G4^C*A9E/LP% &IH_BC2?$ SIEY;W9
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<@ H * "@ H * "@ H * "@ H * "@ H * /_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
